Potential delivery options include injections every three months or a patch as part of a nonhormonal, reversible strategy.

Researchers envision launching a company within two years to push development toward human use, with potential delivery methods including quarterly injections or a transdermal patch.

A Cornell University team has demonstrated a reversible, nonhormonal male contraceptive in mice by temporarily halting sperm production through disrupting meiosis with the molecule JQ1, in a six-year study.

The approach targets prophase I of meiosis in spermatogenesis, halting sperm production while preserving spermatogonial stem cells so fertility can return after stopping treatment and healthy offspring are observed.

When JQ1 is administered for three weeks, sperm production stops completely and fertility resumes within about six weeks after cessation, with offspring that are themselves fertile.

Context in contraception: nonhormonal, reversible options are highly desirable due to limitations or safety concerns with existing methods.

The study was published in PNAS in April 2026 (DOI: 10.1073/pnas.2517498123) and is cited by the Cornell Chronicle as part of ongoing nonhormonal male contraception research.

If adapted to humans, the method could be a periodically administered contraception via injection every few months or a patch to maintain the effect.

The study lays groundwork for safety, dose optimization, and eventual human clinical trials, with implications for public health, gender equity, and shared reproductive responsibility.

Lead geneticist Paula Cohen highlights the novelty and viability of targeting testicular meiotic checkpoints as a contraceptive strategy.

This research addresses the limited current options for male contraception (condoms and vasectomy) by pursuing a nonhormonal, reversible method that could preserve fertility after recovery.

Scientifically, the approach preserves germline stem cells and avoids permanent fertility damage, signaling potential for human trials and broader exploration of targeted meiotic inhibitors.